Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study

Aim To examine improvement in the use of optimal medical therapy (OMT) for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes. Materials and Methods Patients with ASCVD (coronary, cerebrovascular, peripheral) and low‐density lipoprotein‐cholesterol of 7...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-06, Vol.25 (6), p.1750-1757
Hauptverfasser:	Arnold, Suzanne V., Lemos, James A., Zheng, Luke, Rosenson, Robert S., Ballantyne, Christie M., Alam, Shushama, Bhatt, Deepak L., Cannon, Christopher P., Kosiborod, Mikhail
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin Angiotensin II Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Anticoagulants Arteriosclerosis Atherosclerosis Atherosclerosis - drug therapy Atherosclerosis - epidemiology Atherosclerosis - prevention & control Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cholesterol Cholesterol, LDL Cohort analysis Diabetes Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Disease prevention Fibrinolytic Agents Glomerular filtration rate GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 Glucose transporter Heart diseases Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Kexin Lipids Longitudinal Studies Neprilysin Primary care Proprotein convertases Prospective Studies quality of care Subtilisin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aim To examine improvement in the use of optimal medical therapy (OMT) for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes. Materials and Methods Patients with ASCVD (coronary, cerebrovascular, peripheral) and low‐density lipoprotein‐cholesterol of 70 mg/dl or higher were enrolled from December 2016 to July 2018 from 107 US sites/physicians (47% cardiology, 41% primary care, 12% other) and prospectively followed for 2 years (current analysis restricted to subgroup with diabetes). OMT was defined as high‐intensity lipid‐lowering (high‐intensity statin, any statin + ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitor), antithrombotic (antiplatelet or anticoagulant), angiotensin‐converting enzyme‐inhibitor/angiotensin II receptor blocker/angiotensin receptor neprilysin inhibitor (ACE‐I/ARB/ARNI) (excluding glomerular filtration rate [GFR]
ISSN:	1462-8902 1463-1326
DOI:	10.1111/dom.15032